This preprint is under consideration at Journal of Orthopaedic Surgery and Research. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Effect of Denosumab in Preventing Joint Destruction in Rheumatoid Arthritis With Anti-Cyclic Citrullinated Peptide Antibodies
Yu Mori
Tohoku University Garaduate School of medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8225-4690
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Introduction: This study aimed to determine the effects of denosumab treatment on the joint destruction of Japanese females with rheumatoid arthritis (RA) and anti-cyclic citrullinated peptide (CCP) antibodies.
Materials and Methods: This retrospective longitudinal study included 56 patients treated with denosumab and 50 patients treated with bisphosphonate. All participants were positive for anti-CCP antibodies. All patients also had a history of osteoporosis treatment with bisphosphonate, which was either continued or switched to 60 mg of subcutaneous denosumab injection every 6 months. To assess the progression of joint destruction, hand and foot radiographs were taken, and changes in modified total Sharp score (mTSS), erosion score (ERO) and joint space narrowing score (JSN) were evaluated at 12 months and 24 months. The changes in BMD of the lumbar spine and hip were also assessed at 12 months.
Results: At 12 months, there were significant differences in the change of ERO (p = 0.015) and mTSS (p = 0.01). Similarly, there were significant differences in the change of ERO (p = 0.013) and mTSS (p = 0.003) at 24 months. In contrast, no significant difference was observed in the changes of JSN and clinical parameters. There were significant differences in the changes in BMD in the femoral neck (p = 0.011) and total hip (p = 0.012).
Conclusion: Denosumab treatment was effective for the inhibition of bone erosion progression, and it contributes to the treatment of osteoporosis and prevention of destructive arthritis in patients with RA.
Keywords
Denosumab, Rheumatoid arthritis, Anti-cyclic citrullinated peptide antibody, Bone erosion, Joint destruction, Modified total Sharp score
Figure 1
Figure 1
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 18 Dec, 2020
No community comments so far
Editorial decision: Major revision
On 29 Dec, 2020
Review #6 received
Received 28 Dec, 2020
Review #3 received
Received 23 Dec, 2020
Review #2 received
Received 22 Dec, 2020
Review #4 received
Received 19 Dec, 2020
Review #5 received
Received 19 Dec, 2020
Reviewer #6 agreed
On 15 Dec, 2020
Review #1 received
Received 13 Dec, 2020
Reviewer #5 agreed
On 10 Dec, 2020
Reviewer #4 agreed
On 10 Dec, 2020
Reviewer #2 agreed
On 09 Dec, 2020
Reviewer #3 agreed
On 09 Dec, 2020
Reviewers invited
Invitations sent on 09 Dec, 2020
Reviewer #1 agreed
On 09 Dec, 2020
Editor assigned
On 08 Dec, 2020
Submission checks complete
On 08 Dec, 2020
Editor invited
On 08 Dec, 2020
First submitted
On 06 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Orthopedic Surgery
Learn more about our company.
This preprint is under consideration at Journal of Orthopaedic Surgery and Research. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Effect of Denosumab in Preventing Joint Destruction in Rheumatoid Arthritis With Anti-Cyclic Citrullinated Peptide Antibodies
Yu Mori
Tohoku University Garaduate School of medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8225-4690
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 18 Dec, 2020
No community comments so far
Editorial decision: Major revision
On 29 Dec, 2020
Review #6 received
Received 28 Dec, 2020
Review #3 received
Received 23 Dec, 2020
Review #2 received
Received 22 Dec, 2020
Review #4 received
Received 19 Dec, 2020
Review #5 received
Received 19 Dec, 2020
Reviewer #6 agreed
On 15 Dec, 2020
Review #1 received
Received 13 Dec, 2020
Reviewer #5 agreed
On 10 Dec, 2020
Reviewer #4 agreed
On 10 Dec, 2020
Reviewer #2 agreed
On 09 Dec, 2020
Reviewer #3 agreed
On 09 Dec, 2020
Reviewers invited
Invitations sent on 09 Dec, 2020
Reviewer #1 agreed
On 09 Dec, 2020
Editor assigned
On 08 Dec, 2020
Submission checks complete
On 08 Dec, 2020
Editor invited
On 08 Dec, 2020
First submitted
On 06 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Orthopedic Surgery
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Introduction: This study aimed to determine the effects of denosumab treatment on the joint destruction of Japanese females with rheumatoid arthritis (RA) and anti-cyclic citrullinated peptide (CCP) antibodies.
Materials and Methods: This retrospective longitudinal study included 56 patients treated with denosumab and 50 patients treated with bisphosphonate. All participants were positive for anti-CCP antibodies. All patients also had a history of osteoporosis treatment with bisphosphonate, which was either continued or switched to 60 mg of subcutaneous denosumab injection every 6 months. To assess the progression of joint destruction, hand and foot radiographs were taken, and changes in modified total Sharp score (mTSS), erosion score (ERO) and joint space narrowing score (JSN) were evaluated at 12 months and 24 months. The changes in BMD of the lumbar spine and hip were also assessed at 12 months.
Results: At 12 months, there were significant differences in the change of ERO (p = 0.015) and mTSS (p = 0.01). Similarly, there were significant differences in the change of ERO (p = 0.013) and mTSS (p = 0.003) at 24 months. In contrast, no significant difference was observed in the changes of JSN and clinical parameters. There were significant differences in the changes in BMD in the femoral neck (p = 0.011) and total hip (p = 0.012).
Conclusion: Denosumab treatment was effective for the inhibition of bone erosion progression, and it contributes to the treatment of osteoporosis and prevention of destructive arthritis in patients with RA.
Figure 1
Figure 1